Dave Williamson
XMFGreenwave4
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Recent Articles by Dave Williamson

Apr 7, 2017
by Dave Williamson
Time to Buy: Dendreon?

Apr 7, 2017
by Dave Williamson
Time to Buy: Avanir?

Apr 7, 2017
by Dave Williamson
Time to Buy: InterMune?

Apr 7, 2017
by Dave Williamson
Time to Buy: VIVUS?

Apr 7, 2017
by Dave Williamson
Will the Dow See a Fifth Straight Day of Gains?

Apr 7, 2017
by Dave Williamson
3 Health Care Stocks That Won July

Apr 7, 2017
by Dave Williamson
Is the Dow's Mini-Rally Dead?

Apr 7, 2017
by Dave Williamson
Will the Dow's Mini-Rally Last?

Apr 7, 2017
by Dave Williamson
Predicted Failure Still Hurts

Apr 7, 2017
by Dave Williamson
Why the Dow's Hitting 3-Month Highs

Apr 7, 2017
by Dave Williamson
Rising Unemployment = Rising Dow

Apr 7, 2017
by Dave Williamson
Central Bankers Punish the Dow

Apr 7, 2017
by Dave Williamson
Big Pharma + Big Failure = Big Punishment
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.